Orchard’s Gene Therapy Under Fast-Track Review At EMA
Executive Summary
A handful of new products are under review at the European Medicines Agency. Orchard Therapeutics' gene therapy application will be fast-tracked; Roche's filing for its new flu treatment will not.
You may also be interested in...
EU Accelerated Assessment Tracker
The European Medicines Agency this year is known to have granted ten requests for accelerated assessment of planned EU marketing authorization applications. Nine such requests are known to have been rejected. As 2019 draws to a close, the outcomes of five requests are still unknown.
New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
Vascepa Gains European Filing Nod
On the cusp of US approval, Amarin must wait until late 2020 for EMA judgement